您好,欢迎您来到7022至尊国际至尊享受!

血浆蛋白质研究平台

发布时间:2015-01-09 【字号: 浏览次数:
        血浆蛋白质研究平台前身为7022至尊国际至尊享受血浆蛋白质研究室、血液生化与分子生物学研究中心,2010年获批“四川省血浆蛋白质重点实验室”。 自实验室建立以来,长期专注于血浆蛋白质研究,先后研究开发出中国第一支人血白蛋白、肌肉注射免疫球蛋白、静脉注射免疫球蛋白、凝血因子Ⅷ浓缩制剂、凝血酶原复合物、α2-巨球蛋白和铁传递蛋白等10余种血浆蛋白产品及系列血栓与止血诊断产品,获多项省部级以上科研成果。近年来先后承担国家“863”计划重点项目、国家公益性卫生行业科研重大专项、四川省科技攻关项目、四川省科技基础条件平台建设项目、四川省科技支撑计划项目、四川省卫生厅科学研究项目、成都市科技计划项目及多项重大横向合作项目等。本着优势互补、合作共赢、共同发展的原则,分别与中国医学科学院药物所、基础医学所、医学生物学所等科研院所,以及China Biologic Product,Inc和成都协和生物技术有限责任公司共建血液药效组分研究、生物医药研究、医学生物诊断研究、血液综合利用研究以及体外诊断试剂研究等联合实验室。实验室现有科技人员13人,其中高级专业技术职称人员4人,硕士以上学历人员12人。五年来先后在国内外核心学术期刊发表论文超过60篇,国家发明专利20余项。
        主要研究方向:
        主要从事血液相关蛋白与疾病及其疗效机制、血浆蛋白结构与功能相关性研究;血液成分制品安全性、有效性的评价体系建设及检测关键技术与标准化研究;血液相关蛋白质产品及血栓与止血诊断试剂研究开发等。
Research Platform for Blood Plasma Proteins was re-organized from Blood Plasma Proteins Laboratory and Blood Biochemistry and Molecular Biology Research Center of Institute of Blood Transfusion, CAMS/PUMC. It became the Sichuan Provincial Key Laboratory of Human Blood Plasma Proteins in 2010. We have been focusing the research of blood plasma proteins since the establishment of the laboratory. 10 products derived from human blood plasma, including the first Chinese commercial human albumin, intramuscular immunoglobulin (IMIG), intravenous immunoglobulin (IVIG), Factor Ⅷ concentrate, prothrombin complex concentrate, α2-macroglobulin and transferrin, and a series of diagnostic kits for thrombosis and hemostasis have been developed. Several provincial and ministerial achievements have been obtained. We have accomplished projects under National High - Tech Research and Development Program of China (863 Program), Special Projects for National Public Health services, Science and Technology Development Programs of Sichuan, The R&D Infrastructure and Facility Development Program of Sichuan, Key Technology Research and Development Program of Sichuan, Science and Technology Development Programs of Sichuan Provincial Commission of Health and Family Planning, Science and Technology Development Programs of Chengdu and also industrial cooperative projects. Based on the principle of complementary advantages, win-win cooperation and common development, we established Joint Laboratory for Research on Efficacy of Blood Components with Institute of Materia Medica, CAMS/PUMC, Joint Laboratory for Biomedical Research with Institute of Basic Medical Sciences, CAMS/PUMC, Joint Laboratory for Diagnosis and Medical Biology with Institute of Medical Biology, CAMS/PUMC, Joint Laboratory for Comprehensive Utilization of Blood with China Biologic Products, Inc. and Joint Laboratory for In Vitro Diagnostics with Chengdu Union Biotechnology Co, LTD.. With 13 staffs, including 5 senior engineers and 12 masters and doctors, we have published more than 60 papers and obtained 20 approved patents.
 Research Focus
We are interested in investigating the structure and function of blood plasma proteins and their therapeutic application in various diseases; evaluation of safety and efficacy of blood component products and their standardization of detection and preparation; development of blood plasma products and diagnostic kits for thrombosis and hemostasis.
\

PI简介:

李长清
        教授,研究生导师,从事输血医学及血液相关技术与产品研究24年。1995年年仅27岁即被中国医学科学院破格晋升为副研究员,历任7022至尊国际至尊享受蛋白室副主任、主任,血液制品部(技术开发部)副主任,生物技术中心主任,血液生化与分子生物学研究中心主任、四川省血浆蛋白质重点实验室主任;血液安全处处长等职。现任国家血液安全督导检查组专家、中国输血杂志编委、中国输血协会血液制品委员会委员、四川省输血协会血液制品委员会副主任委员、四川医学会委员、四川生化与分子生物学会理事等。主要从事血液相关蛋白与疾病及其疗效机制、血浆蛋白结构与功能相关性研究;血液成分制品安全性、有效性的评价体系建设及检测关键技术与标准化研究;血液相关蛋白质产品研究开发。
         曾先后参与人血白蛋白、免疫球蛋白、Ⅷ因子、PCC等多种血浆蛋白制品的研究开发,其中“利凡诺-低温乙醇结合法分离血浆蛋白新工艺研究”获四川省科技进步一等奖;“中纯Ⅷ因子制剂的研制”获四川省科技进步二等奖。近5年来又先后主持承担四川省科技计划支撑项目“血液制品生产废弃组分再利用技术开发研究”、国家公益性卫生行业科研重大专项 “输血安全相关技术与标准研究”、“报废血再利用技术应用研究”以及国家科技重大专项“863”计划项目“血液制品综合纯化新工艺研究及产品开发”、四川省科技计划项目“血液制品深度开发关键技术及相关产品产业化开发”等项目。近年来,先后在国内外科技核心期刊发表论文近50篇,国家发明专利20余项。
Tel:86-28-61648506        E-mail: lichangqing268@163.com
Changqing Li, professor at Inand supervisor for postgraduates, has been engaged in research of blood transfusion medicine and related technologies and products for 24 years. He worked as an associate professor at CAMS when he was only 27 in 1995. He served as deputy director and director of the department of protein, deputy director of the department of blood products, director of biotechnology center, director of blood biochemistry and molecular biology research center, director of Sichuan Provincial Key Laboratory of Human Blood Plasma Proteins, director of blood safety promotion department, etc. He is an expert in National Blood Safety Supervision Inspection Group, member of Editorial board of Chinese Journal of Blood Transfusion, member of blood products committee of CSBT, etc. His main research areas are the structure and function of plasma protein, establishment and standardization of the security and efficacy of blood products, R&D of blood products, etc.
Professor Li participated in the R&D of human albumin, IVIg, FVIII, PCC, etc. As one of the main participants, “rivanol-cold ethanol fractionation of plasma proteins” was awarded “the first prize of science and technology progress prize of Sichuan province” and “R&D of medium-purity coagulation factor Ⅷ” was awarded “the second prize of science and technology progress prize of Sichuan province”. In the last 5 years, he has been funded by Provincial Science and technology support program of Sichuan, special fund for Public Welfare Industry of Health and 863 program. In addition, he has published almost 50 papers and more than 20 patents.

林方昭
        副主任技师。主要从事血栓与止血检验技术及产品的研发与产业化,血液相关蛋白成分与出凝血疾病的相关性研究,血液制品有效性、安全性评价及评价体系标准化研究,单克隆抗体制备技术研究以及对外检测技术服务等。近年来承担四川省科技支撑计划项目“血栓与止血系列诊断试剂(盒)及配套仪器的研究开发”,四川省卫生厅科学研究项目“系列凝血质控物的研制与开发”,成都市科技局产学研联合实验室项目“血液病诊断联合实验室”和20余项横向合作项目等,累计立项经费350余万元。作为项目负责人之一,完成了六种凝血诊断产品的研发及产品文号申报等工作,取得了6种凝血诊断产品生产文号。申请国家发明专利6项,在国内外核心期刊发表论文20余篇。 
Tel:86-28-61648541        E-mail: lfangzhao@126.com                                 
Fangzhao Lin, born in 1966, is associate chief technician at IBT, CAMS/PUMC. She has been engaged in 1) research, development and industrialization of laboratory technology in thrombosis and hemostasis, 2) relationship between blood proteins and bleeding/thrombotic disorders, 3) efficacy, evaluation of safety and its standardization of blood products, 4) monoclonal antibody preparation and 5) laboratory testing services. Recent years, she has accomplished projects with funds of ~¥3.5 million supported by Key Technology Research and Development Program of Sichuan (Development of diagnostic kits and instruments for thrombosis and hemostasis), Science and Technology Development Programs of Sichuan Provincial Commission of Health and Family Planning (research and development of a series of coagulation factor controls) and Industry - Academy - Research Projects of Chengdu Science and Technology Bureau (Establishment of joint laboratory for diagnostic of hematologic diseases), and also 20 industrial cooperative projects. As one of the responsible persons, she got 6 official approvals for diagnosis of coagulation factors, 6 approved national invention patents and published about 20 papers.

Baidu
sogou